Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. On behalf of Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) please find below our article of the week. 3-year follow up of the phase III CASTOR study with independent expert commentary provided by MSAG chair Professor H. Miles Prince AM (Research...Continue Reading

Welcome to issue 37 of Multiple Myeloma Research Review. This issue begins with a retrospective, multinational report describing the clinical features associated with outcomes of patients with MM who had acquired SARS-COV-2 infection. There is also research demonstrating that autologous HSCT is an important therapy among patients with MM, even our elderly patients. Researchers from...Continue Reading

Come along to our Auckland Myeloma Patient Seminar, hosted by Myeloma New Zealand.  We will hear from Dr Henry Chan (Waitemata DHB), Dr Nicole Chien (Auckland DHB), Dr Ken Romeril and nursing staff from Auckland and North Shore Hospitals.Continue Reading

This article was originally published on Cure While a diagnosis of multiple myeloma can be overwhelming for patients, the disease is very treatable, according to Dr. Andrew Yee. At CURE®’s Educated Patient® Summit on Multiple Myeloma, Yee, an assistant professor of medicine at Massachusetts General Hospital Cancer Center in Boston, discussed the signs and symptoms of...Continue Reading

This article was originally published on Wiley Online Library There are currently limited Australian data on the outcomes of autologous stem cell transplantation (ASCT) in elderly multiple myeloma (MM) patients. We present the largest cohort of elderly MM patients aged ≥65 years undergoing ASCT in Australia and report their outcomes based on our two‐centre experience. Our...Continue Reading

This article was originally posted on AJMC Multiple myeloma is not easily diagnosed, and its early symptoms may be confused for another condition. Each March, Multiple Myeloma Awareness Month puts multiple myeloma (MM) in the spotlight. A rare cancer, MM is not easily diagnosed early on, but it is the second most common blood cancer...Continue Reading

This article was originally published by Urbanhealth Today ABSTRACT BACKGROUND: The current standard of care for multiple myeloma requires several regimens of treatment, with patients experiencing high symptom burden and side effects, which negatively impact health-related quality of life (HRQoL). Thus, it is crucial to understand patient perceptions of multiple myeloma and how patients value...Continue Reading

Dear All We have had a mixed summer with some parts of the country sweltering and other parts not so much. There appears to be some light at the end of the Covid tunnel with the slow roll out of the vaccine program. We would hope that our older and immune-compromised folk would be vaccinated...Continue Reading

I have recently completed the Alps 2 Ocean (A2O) 315km ride over 6 days which is one of my greatest physical accomplishments in recent times and have been asked to write something about my journey. I will start with myself. Diagnosed with Kappa Light Chain myeloma 8.5 years ago after the T9 on my spinal...Continue Reading

This article was originally published on News Medical Life Sciences Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells’ metabolism. These changes can be used as...Continue Reading